Boundless Bio, Inc. (BOLD) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.32
+8% vs avg
5yr avg: 0.30
30Y Low0.3·High0.3
ROE
↓
-46.7%
↓+77% vs avg
5yr avg: -204.7%
30Y Low-65%·High-12%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BOLD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Boundless Bio, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $32M | $27M | $49M | — | — | — | — | — | — |
| Enterprise Value | $63M | $58M | $70M | — | — | — | — | — | — |
| P/E Ratio → | -0.55 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.32 | 0.27 | 0.33 | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BOLD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
BOLD Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -46.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -46.7% | -46.7% | -554.9% | — | — | -12.5% | -43.0% | -65.4% | -50.0% |
| ROA | -32.0% | -32.0% | -38.9% | -47.8% | -48.2% | -8.6% | -39.6% | -56.3% | -42.0% |
| ROIC | -31.6% | -31.6% | -475.9% | — | — | -16.3% | -46.8% | -66.4% | -52.5% |
| ROCE | -37.1% | -37.1% | -46.0% | -57.8% | -51.9% | -9.1% | -44.1% | -64.2% | -46.4% |
BOLD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $31M ($49M total debt minus $18M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.50 | 0.50 | 0.32 | — | — | — | 0.02 | 0.05 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.32 | 0.14 | — | — | — | -0.31 | -0.20 | -0.28 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
BOLD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Boundless Bio, Inc.'s current ratio of 8.74x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 13.27x to 8.74x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.74 | 8.74 | 18.98 | 13.27 | 8.80 | 19.28 | 17.60 | 7.74 | 8.63 |
| Quick Ratio | 8.74 | 8.74 | 18.98 | 13.27 | 8.80 | 19.28 | 17.60 | 7.74 | 8.63 |
| Cash Ratio | 8.58 | 8.58 | 18.70 | 12.90 | 8.63 | 18.89 | 17.37 | 7.54 | 8.35 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
BOLD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Boundless Bio, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $22M | $17M | $22M | $22M | $22M | $44M | $27M | $11M |
Peer Comparison
Compare BOLD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BOLDYou | $32M | -0.6 | — | — | — | — | -46.7% | -31.6% | — |
 MGNX | $263M | -3.5 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 TPVG | $203M | 4.1 | 8.6 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 KYMR | $7B | -24.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 AGEN | $125M | -882.4 | — | — | 29.6% | -18.0% | — | — | — |
 IDYA | $3B | -24.4 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 AUPH | $2B | 8.0 | 18.5 | 15.6 | 88.5% | 37.1% | 59.9% | 16.6% | 0.7 |
 TNGX | $3B | -32.1 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 PMVP | $60M | -0.8 | — | — | — | — | -55.4% | -63.4% | — |
 PRME | $583M | -2.4 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BOLD — Frequently Asked Questions
Quick answers to the most common questions about buying BOLD stock.
What is Boundless Bio, Inc.'s P/E ratio?
Boundless Bio, Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
What is Boundless Bio, Inc.'s ROE?
Boundless Bio, Inc.'s return on equity (ROE) is -46.7%. The historical average is -43.5%.
Is BOLD stock overvalued?
Based on historical data, Boundless Bio, Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.